

PURE BIOSCIENCE, INC.  
Form 8-K  
October 09, 2013

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): October 8, 2013**

**PURE BIOSCIENCE, INC.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State or Other Jurisdiction of**  
**Incorporation)**

**001-14468**  
**(Commission**

**File Number)**  
**1725 Gillespie Way**

**El Cajon, California 92020**

**33-0530289**  
**(IRS Employer**

**Identification Number)**

Edgar Filing: PURE BIOSCIENCE, INC. - Form 8-K

**(Address of Principal Executive Offices)**

**(619) 596-8600**

**(Registrant's telephone number including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 8, 2013, PURE Bioscience, Inc. (the Company ) announced the appointment of William Otis as a new member of its Board of Directors. There is no arrangement or understanding between Mr. Otis and any other person pursuant to which he was elected as a director. In addition, there are no transactions in which Mr. Otis has an interest in requiring disclosure under Item 404(a) of Regulation S-K.

The Company issued a press release announcing the appointment of Mr. Otis to its Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibit is furnished with this report:

Exhibit No.	Exhibit Description
99.1	Press Release issued by the Company on October 8, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PURE BIOSCIENCE, INC.**

Dated: October 9, 2013

By: /s/ Hank Lambert  
Hank Lambert,  
Chief Executive Officer